The announcement of a registered direct offering by ASLAN Pharmaceuticals is a significant financial activity that could have various implications. While it indicates the company's ability to raise capital, the direct impact on the stock price in the short term is uncertain. It could be perceived positively as a move towards growth or negatively due to potential dilution of shares. Hence, a neutral score is assigned.